Market Overview

MacroGenics Enters License Agreement with Gilead Sciences to Develop and Commercialize Four DART Products

MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced it has entered into a license agreement with Gilead Sciences, Inc. (Nasdaq: GILD) for the development and commercialization of Dual-Affinity Re-Targeting (DART™) products directed at up to four undisclosed targets.  MacroGenics' DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens.

"We look forward to building a long-term collaboration with MacroGenics, a leader in the development of bi-specific antibodies, which represents a promising new area of research,"
said Roy D.

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (GILD)

Around the Web, We're Loving...

Get Benzinga's Newsletters